Skip to main content
Clinical Trials/JPRN-UMIN000042905
JPRN-UMIN000042905
Recruiting
Phase 3

Postoperative radiotherapy (PORT) for pathological N2 non-small cell lung cancer with adjuvant chemotherapy: a randomized phase III trial - Postoperative radiotherapy (PORT) for pathological N2 non-small cell lung cancer with adjuvant chemotherapy: a randomized phase III trial

Japan Clinical Oncology Group (JCOG)0 sites330 target enrollmentJanuary 5, 2021

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
pathological N2 non-small cell lung cancer
Sponsor
Japan Clinical Oncology Group (JCOG)
Enrollment
330
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 5, 2021
End Date
January 5, 2032
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japan Clinical Oncology Group (JCOG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)History of synchronous or metachronous (within 3 years) malignancies (2\)Active infection requiring systemic therapy (3\)Fever with a body temperature higher than 38\.0 degrees Celsius at the time of registration (4\)Pregnant, possibly pregnant, within 28 days of delivery, breastfeeding females, or males expecting to father a child (5\)Psychiatric illnesses or symptoms affecting the daily lives (6\)Systemic treatment with steroids or immunosuppressive agents (7\)Unstable angina(diagnosis or worsening of chest pain within 3 weeks) or history of myocardial infarction within 6 months prior to the registration

Outcomes

Primary Outcomes

Not specified

Similar Trials